Presepsin Values Evaluated as Sepsis Severity Markers
|
By LabMedica International staff writers Posted on 23 Jun 2020 |

Image: Presepsin concentrations (ng/mL) in two severity groups. Black line: sepsis patients; black dotted line: septic shock patients (Photo courtesy of University Hospital for Infectious Diseases in Zagreb).
Sepsis is a life-threatening condition, with poor and highly variable clinical manifestations, difficult to identify and diagnose. Sepsis has remained a real diagnostic challenge to clinicians, causing millions of death worldwide each year. Early recognition of sepsis is crucial for better disease outcome.
Blood cultures are a gold standard for diagnosing sepsis. Despite the great advantages, blood cultures also have some limitations as they are often negative, especially in patients previously treated with antibiotic, and their results are usually obtained over several days. While waiting for blood culture results, treatment of critically ill septic patients may be delayed, increasing the possibility of poor outcome.
Infectious disease specialist at the University Hospital for Infectious Diseases (Zagreb, Croatia) and their colleagues conducted a prospective observational study in two university clinical centers and enrolled 100 septic patients during two time periods. New Sepsis-3 definitions were used for sepsis stratification. Biomarkers and SOFA score were evaluated four times during the illness.
Routine laboratory parameters and C-reactive protein (CRP) were tested immediately. For procalcitonin (PCT) and presepsin levels measurements, blood was collected at all four time points, frozen until the end of the study, and then measured. Quantitative analysis of PCT was performed using an automated electrochemiluminescence immunoanalyzer (ELECSYS* BRAHMS* PCT; Roche Diagnostics, Mannheim, Germany). A sandwich enzyme-linked immune-sorbent assay ̶ Human Presepsin ELISA Kit (Nordic Biosite, Täby, Sweden), was used for presepsin measurement.
The following laboratory parameters were recorded: red blood cell count, hemoglobin, hematocrit, white blood cell count, platelet count, serum creatinine, serum total bilirubin, serum liver enzymes (aspartate aminotransferase-AST and alanine aminotransferase-ALT), partial thromboplastin time (PTT), international normalized ratio (INR), electrolytes (sodium and potassium), blood gas analysis, CRP, PCT, and presepsin concentrations.
The scientists reported that presepsin concentrations were significantly higher on admission in 34 patients with septic shock compared to 66 patients with sepsis, mean ± SD: 128.5 ± 47.6 ng/mL versus 88.6 ± 65.6 ng/mL, respectively. The same was not observed for PCT and CRP; their concentrations did not differ significantly between severity groups. A strong correlation of presepsin with SOFA score was also found.
The authors concluded that their study showed that serum presepsin concentration on admission reflects the severity of disease. Presepsin was a better predictor of multiple organ dysfunction syndrome compared to other tested sepsis biomarkers. The strong correlation of presepsin with SOFA score makes this marker a valuable tool for identifying septic patients. PCT and CRP concentrations did not differ between sepsis severity groups. The study was published in the June, 2020 issue of the International Journal of Infectious Diseases.
Blood cultures are a gold standard for diagnosing sepsis. Despite the great advantages, blood cultures also have some limitations as they are often negative, especially in patients previously treated with antibiotic, and their results are usually obtained over several days. While waiting for blood culture results, treatment of critically ill septic patients may be delayed, increasing the possibility of poor outcome.
Infectious disease specialist at the University Hospital for Infectious Diseases (Zagreb, Croatia) and their colleagues conducted a prospective observational study in two university clinical centers and enrolled 100 septic patients during two time periods. New Sepsis-3 definitions were used for sepsis stratification. Biomarkers and SOFA score were evaluated four times during the illness.
Routine laboratory parameters and C-reactive protein (CRP) were tested immediately. For procalcitonin (PCT) and presepsin levels measurements, blood was collected at all four time points, frozen until the end of the study, and then measured. Quantitative analysis of PCT was performed using an automated electrochemiluminescence immunoanalyzer (ELECSYS* BRAHMS* PCT; Roche Diagnostics, Mannheim, Germany). A sandwich enzyme-linked immune-sorbent assay ̶ Human Presepsin ELISA Kit (Nordic Biosite, Täby, Sweden), was used for presepsin measurement.
The following laboratory parameters were recorded: red blood cell count, hemoglobin, hematocrit, white blood cell count, platelet count, serum creatinine, serum total bilirubin, serum liver enzymes (aspartate aminotransferase-AST and alanine aminotransferase-ALT), partial thromboplastin time (PTT), international normalized ratio (INR), electrolytes (sodium and potassium), blood gas analysis, CRP, PCT, and presepsin concentrations.
The scientists reported that presepsin concentrations were significantly higher on admission in 34 patients with septic shock compared to 66 patients with sepsis, mean ± SD: 128.5 ± 47.6 ng/mL versus 88.6 ± 65.6 ng/mL, respectively. The same was not observed for PCT and CRP; their concentrations did not differ significantly between severity groups. A strong correlation of presepsin with SOFA score was also found.
The authors concluded that their study showed that serum presepsin concentration on admission reflects the severity of disease. Presepsin was a better predictor of multiple organ dysfunction syndrome compared to other tested sepsis biomarkers. The strong correlation of presepsin with SOFA score makes this marker a valuable tool for identifying septic patients. PCT and CRP concentrations did not differ between sepsis severity groups. The study was published in the June, 2020 issue of the International Journal of Infectious Diseases.
Latest Clinical Chem. News
- Blood Test Detects More High-Risk Prostate Cancers Than PSA
- Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
- Blood-Based Alzheimer’s Testing Platform Offers Rapid Results
- Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
- Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
- Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
- Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
- Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
- Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
Channels
Molecular Diagnostics
view channel
Genomic Test Guides Taxane-Based Chemotherapy Selection in Breast Cancer
Selecting adjuvant chemotherapy for hormone receptor–positive, HER2-negative (HR+/HER2−) breast cancer remains challenging because current genomic assays mainly estimate recurrence risk rather than predict... Read more
RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis
Alzheimer’s disease affects an estimated 55 million people worldwide and remains difficult to diagnose at an early stage. Diagnostic workups can be complicated by symptom overlap with other conditions,... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. For immunotherapy evaluation, the precise sequence... Read more
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreMicrobiology
view channel
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read more
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Partnership Aims to Improve Transplant Monitoring Across Care Continuum
Allograft rejection and chronic graft dysfunction remain major challenges in solid organ transplantation, requiring careful immunologic matching and long-term surveillance. Fragmented pre- and post-transplant... Read more
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more




.jpg)



